Exchange Traded Concepts LLC Has $1.16 Million Position in Revvity, Inc. (NYSE:RVTY)

Exchange Traded Concepts LLC raised its stake in shares of Revvity, Inc. (NYSE:RVTY) by 2.2% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 9,088 shares of the company’s stock after purchasing an additional 193 shares during the period. Exchange Traded Concepts LLC’s holdings in Revvity were worth $1,161,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Rothschild Investment LLC acquired a new position in Revvity in the 2nd quarter valued at $25,000. EverSource Wealth Advisors LLC grew its position in shares of Revvity by 74.2% in the second quarter. EverSource Wealth Advisors LLC now owns 392 shares of the company’s stock valued at $41,000 after purchasing an additional 167 shares during the last quarter. Fairfield Financial Advisors LTD bought a new position in shares of Revvity in the second quarter worth about $43,000. Family Firm Inc. acquired a new position in shares of Revvity during the 2nd quarter worth about $43,000. Finally, EntryPoint Capital LLC acquired a new position in shares of Revvity during the 1st quarter worth about $48,000. Institutional investors own 86.65% of the company’s stock.

Revvity Trading Down 3.3 %

RVTY stock opened at $120.21 on Thursday. Revvity, Inc. has a 1-year low of $79.50 and a 1-year high of $128.15. The company has a current ratio of 2.27, a quick ratio of 1.98 and a debt-to-equity ratio of 0.40. The business’s 50 day moving average is $121.60 and its 200-day moving average is $112.82. The firm has a market cap of $14.83 billion, a P/E ratio of 99.35, a P/E/G ratio of 3.35 and a beta of 1.05.

Revvity (NYSE:RVTY) last announced its quarterly earnings results on Monday, July 29th. The company reported $1.22 earnings per share for the quarter, beating analysts’ consensus estimates of $1.12 by $0.10. The firm had revenue of $691.70 million for the quarter, compared to analysts’ expectations of $690.33 million. Revvity had a return on equity of 7.34% and a net margin of 6.26%. The business’s revenue was down 2.5% compared to the same quarter last year. During the same period in the prior year, the business posted $1.21 earnings per share. Equities analysts anticipate that Revvity, Inc. will post 4.75 earnings per share for the current fiscal year.

Revvity Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, November 8th. Investors of record on Friday, October 18th will be issued a dividend of $0.07 per share. This represents a $0.28 annualized dividend and a yield of 0.23%. The ex-dividend date is Friday, October 18th. Revvity’s dividend payout ratio is currently 23.14%.

Wall Street Analysts Forecast Growth

Several research analysts have commented on the company. Barclays raised Revvity from an “equal weight” rating to an “overweight” rating and lifted their price target for the stock from $125.00 to $140.00 in a research report on Tuesday. Leerink Partnrs upgraded shares of Revvity to a “strong-buy” rating in a research note on Monday, July 8th. JPMorgan Chase & Co. raised their price target on shares of Revvity from $105.00 to $120.00 and gave the stock a “neutral” rating in a research report on Tuesday, July 30th. TD Cowen upped their price objective on shares of Revvity from $130.00 to $141.00 and gave the company a “buy” rating in a research report on Tuesday, July 30th. Finally, Wells Fargo & Company began coverage on Revvity in a research report on Tuesday, August 27th. They set an “equal weight” rating and a $130.00 target price on the stock. Seven investment analysts have rated the stock with a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $126.53.

Insider Buying and Selling at Revvity

In other news, insider Tajinder S. Vohra sold 2,154 shares of Revvity stock in a transaction that occurred on Wednesday, October 9th. The shares were sold at an average price of $121.73, for a total value of $262,206.42. Following the completion of the transaction, the insider now owns 19,652 shares in the company, valued at approximately $2,392,237.96. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In other news, insider Tajinder S. Vohra sold 2,153 shares of the stock in a transaction on Monday, October 7th. The stock was sold at an average price of $122.09, for a total transaction of $262,859.77. Following the sale, the insider now owns 23,960 shares in the company, valued at approximately $2,925,276.40. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Tajinder S. Vohra sold 2,154 shares of Revvity stock in a transaction dated Wednesday, October 9th. The shares were sold at an average price of $121.73, for a total value of $262,206.42. Following the completion of the transaction, the insider now directly owns 19,652 shares of the company’s stock, valued at $2,392,237.96. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 7,807 shares of company stock worth $937,576 over the last ninety days. Corporate insiders own 0.60% of the company’s stock.

Revvity Company Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.